Asarpota assumes responsibilities from Peter Stone, who served as ApiJect's acting chief financial officer. Stone continues at ApiJect in his role as Head of M&A and executive vice president.
Asarpota joins ApiJect after his most recent role as executive vice president, chief financial officer with NuVasive, where he was involved with supporting the company's growth strategy through innovation and driving increased profitability with operating excellence. Prior to that he spent 2 years in the private equity space at Imaging Advantage as executive vice president and chief financial officer which was acquired by Envision in 2015 and at Cole Parmer as COO and CFO.
In 2014, he served as the executive vice president and chief financial officer for Questcor Pharmaceuticals which was acquired by Mallinckrodt in a $5.6 billion transaction. Asarpota also spent a decade at Life Technologies, a global Life Sciences company where he was responsible for helping scale the company with a commercial turnaround, driving growth through organic and M&A channels. During his tenure, the company revenue grew from ~$1 billion in 2014 to $4 billion, leading to the company's sale to Thermo Fisher for $16 billion in 2013.
"Raj comes to us with a wide range of accomplishments in financial management and corporate governance in pharma-related and health solutions industries. He is an innovative thinker who combines a visionary, mission-driven approach with many years of real-world industry and business leadership. He will fit in seamlessly with our senior management team that combines expertise in their functions and a vast bio-pharma experience,” commented Franco Negron, ApiJect's CEO.
"ApiJect's role in the battle against COVID-19 puts it at the center of the most vital health challenge of our time. I'm excited and honored to partner with the talented and experienced team that Franco and our chairman and co-founder, Jay Walker, and co-founder Marc Koska have put together over the past several years,” said Asarpota. “I know that Jay and Marc were not anticipating a global pandemic when they started ApiJect three years ago. But their vision of a company to lead a global transformation of a safe and cost-effective injection technology platform has enabled ApiJect to swiftly answer our nation's call to join a united industry effort to turn the tide against COVID-19, and to bring the benefits of prefilled single-dose injection to a range of longer-term world-wide pharmaceutical uses, including branded and generic pharmaceuticals."